This study specifically recruits individuals currently being prescribed for tirzepatide. The experimental design will consist of a brief discontinuation of the drug for roughly 3-4 weeks followed by a reinitiation of the medication. Prescription and administration of tirzepatide is done as part of normal patient care and is not a component of the study.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18-70 years.
Currently on tirzepatide.
Currently receiving care from University of Texas- Southwestern (UTSW) Weight Wellness Clinic.
Cognitively capable of understanding and signing informed consent.
Be proficient in English.
You may not be if
History of major neurological or psychiatric disorders, including substance use disorders that might confound brain imaging results (e.g., stroke, epilepsy, multiple sclerosis, schizophrenia, major depression requiring hospitalization).
Diagnosis of Type 2 Diabetes.
Current diagnosis of an eating disorder.
Use of medications affecting weight other than tirzepatide.
Pregnancy or breastfeeding.
MR contraindications:
Heart pacemaker, heart valve replacement, or aortic clips
Metal fragments in the eyes, skin, or elsewhere in the body
Brain clips or pieces of metal used in aneurysm surgery or intercranial bypass
Venous umbrella
Pieces of metal in the body resulting from work as a sheet-metal worker or welder
Clips placed in an internal organ
Prosthetic devices, such as middle ear, eye, joint, or penile implants
Joint replacement
Hearing aid that cannot be removed
Neurostimulator
Insulin pump
Shunts or stents
Metal mesh or coil implants
Metal plate, pin, screws, or wires, or any other metal implants
